TBG Diagnostics (TDLAF) Stock Price, News & Analysis

Company Overview

TBG Diagnostics plc (OTCMKTS:TDLAF) is a UK‐based life sciences company specializing in the development, manufacture and commercialization of advanced diagnostic solutions. The company’s core focus lies in point‐of‐care testing, molecular diagnostics and bespoke clinical laboratory services designed to address a range of disease areas, from metabolic disorders to infectious diseases. Through its integrated business units, TBG Diagnostics aims to provide healthcare professionals and research institutions with rapid, accurate and cost‐effective tools for disease detection, monitoring and management.

Its product portfolio is organized into complementary divisions: TBG Bloodspot offers proprietary sampling cards and reagents for dried blood spot collection, facilitating newborn screening, therapeutic drug monitoring and remote patient testing. TBG Breath leverages non‐invasive breath analysis technology to identify biomarkers related to gastrointestinal health, diabetes management and respiratory conditions. The TBG Molecular unit delivers point‐of‐care PCR solutions, combining automated workflow instruments with assay kits for rapid pathogen detection. Additionally, the company’s Contract Development and Manufacturing Organization (CDMO) provides assay development, scale‐up and regulatory support to diagnostics and life sciences customers.

Founded through the consolidation of several niche diagnostic businesses, TBG Diagnostics has expanded its footprint via strategic partnerships, acquisitions and joint ventures. The company maintains manufacturing and R&D facilities in Europe and North America, while its distribution network spans Asia‐Pacific, Latin America and parts of the Middle East. Over time, TBG Diagnostics has cultivated collaborations with academic centers, clinical laboratories and global health organizations to accelerate the adoption of its technologies in both developed and emerging markets.

Guided by an experienced board of directors and a management team drawn from leading diagnostic and biotech firms, TBG Diagnostics emphasizes operational excellence, regulatory compliance and innovation. The company continues to invest in new assay development and digital health initiatives, with the goal of broadening its diagnostic menu and enhancing data‐driven decision making in clinical practice. Through its strategic growth initiatives, TBG Diagnostics seeks to strengthen its position as a versatile partner in the global diagnostics landscape.

Key Stats

• Today's Range: $0.04 to $0.13
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.01 to $0.13
• Volume: 3,200 shs
• Average Volume: 6,655 shs
• Market Capitalization: $2.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TDLAF Stock Analysis - Frequently Asked Questions

How have TDLAF shares performed this year?

TBG Diagnostics' stock was trading at $0.0430 at the beginning of 2025. Since then, TDLAF shares have increased by 0.0% and is now trading at $0.0430.

How do I buy shares of TBG Diagnostics?

Shares of TDLAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medicinals & Botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:TDLAF
• CIK: N/A
• Web: www.tbgbio.com
• Phone: 61 7 3088 7926
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.33 million
• Price / Sales: 1.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,290,000
• Free Float: N/A
• Market Cap: $2.38 million
• Optionable: Not Optionable
• Beta: -12.38